Last reviewed · How we verify

Peginterferon alfa 2 A — Competitive Intelligence Brief

Peginterferon alfa 2 A (Peginterferon alfa 2 A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alpha. Area: Immunology, Virology, Oncology.

marketed Interferon alpha Interferon-alpha receptor (IFNAR) Immunology, Virology, Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Peginterferon alfa 2 A (Peginterferon alfa 2 A) — Dr. Conrado Fernandez. Peginterferon alfa-2a is a pegylated interferon that activates innate immune responses by binding to interferon-alpha receptors, enhancing antiviral and antiproliferative activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Peginterferon alfa 2 A TARGET Peginterferon alfa 2 A Dr. Conrado Fernandez marketed Interferon alpha Interferon-alpha receptor (IFNAR)
Intron A INTERFERON ALFA-2B Merck & Co. marketed Interferon alpha 1986-01-01
Peginterferon alfa-2a 40KD and Ribavirin Peginterferon alfa-2a 40KD and Ribavirin NORDynamIC Study Group marketed Interferon alpha with nucleoside analog Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
Pegylated Interferon Alfa 2a Pegylated Interferon Alfa 2a Vertex Pharmaceuticals Incorporated marketed Interferon alpha Interferon-alpha receptor (IFNAR)
Pegylated Interferon alpha-2a Pegylated Interferon alpha-2a ANRS, Emerging Infectious Diseases marketed Interferon alpha Interferon-alpha receptor (IFNAR)
Placebo and peginterferon Placebo and peginterferon National Taiwan University Hospital marketed Interferon alpha (pegylated) Interferon-alpha receptor (IFNAR)
Peginterferon alfa-2a with Ribavirin Peginterferon alfa-2a with Ribavirin National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) marketed Interferon alpha with nucleoside analog Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alpha class)

  1. Dr. Conrado Fernandez · 2 drugs in this class
  2. Ain Shams University · 1 drug in this class
  3. Beijing 302 Hospital · 1 drug in this class
  4. Foundation for Liver Research · 1 drug in this class
  5. Hoffmann-La Roche · 1 drug in this class
  6. Kexing Biopharm Co., Ltd. · 1 drug in this class
  7. Merck & Co. · 1 drug in this class
  8. ANRS, Emerging Infectious Diseases · 1 drug in this class
  9. Vertex Pharmaceuticals Incorporated · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Peginterferon alfa 2 A — Competitive Intelligence Brief. https://druglandscape.com/ci/peginterferon-alfa-2-a. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: